Please provide your email address to receive an email when new articles are posted on . Among patients with alcoholic-related liver disease in early stages, 15% progressed to decompensation and 22% ...

Please provide your email address to receive an email when new articles are posted on . Patients who used statins had a reduced risk for HCC, hepatic decompensation and fibrosis progression.

Ramat Gan, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and ...

MILAN — Liver transplantation improves survival in patients with acute-on-chronic liver failure (ACLF), according to interim clinical outcomes of the large, international CHANCE study. To date, the ...

Bristol-Myers Squibb announced the approval of Baraclude (entecavir tablets) for the treatment of chronic hepatitis B (CHB) in adult patients with decompensated liver disease. This approval was based ...

Chronic liver disease and even cirrhosis can go unnoticed for a long time because many patients have no symptoms: the liver suffers silently. When the body is no longer able to compensate for the ...

The severity of HBV cirrhosis can be determined by periodic clinical examination and measurement of serum albumin, bilirubin, and prothrombin time. The Child-Turcotte-Pugh (CTP) score and Model for ...

(RTTNews) - Can-Fite BioPharma Ltd. (CANF), announced on Tuesday that a patient experienced the disappearance of episodes of decompensated liver cirrhosis following treatment with Namodenoson under a ...

When the body can no longer compensate the gradual failure of the liver caused by liver cirrhosis, there is a high risk of acute decompensated liver cirrhosis. In some patients this develops quickly ...

Can-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use Setting Liver organ shortage puts patients at risk of death from decompensated cirrhosis with no ...